TABLE OF CONTENTS

COMMENTARY

William M.P. Klein, Alexander J. Rothman, and Jerry Suls on behalf of the NCI Cognitive, Affective, and Social Processes in Health Research (CASPHR) Working Group

343  Conceptualizing Health Behaviors as Acute Mood-Altering Agents: Implications for Cancer Control
Genevieve F. Dunton, Jonas T. Kaplan, John Monterosso, Raina D. Pang, Tyler B. Mason, Matthew G. Kirkpatrick, Sandrah P. Eckel, and Adam M. Leventhal

RESEARCH BRIEF

351  Cancer Immunoprevention: A Case Report Raising the Possibility of “Immuno-interception”
Jessica G. Mancuso, William D. Foulkes, and Michael N. Pollak

RESEARCH ARTICLES

357  Black Raspberry Inhibits Oral Tumors in Mice Treated with the Tobacco Smoke Constituent Dibenzo(def,p)chrysene Via Genetic and Epigenetic Alterations

367  Risk of Prostate Cancer-related Death Following a Low PSA Level in the PLCO Trial
Rebecca Landy, Lauren C. Houghton, Christine D. Berg, Robert L. Grubb III, Hormuzd A. Katki, and Amanda Black

377  Epidemiologic Risk Factors in a Comparison of a Barrett Esophagus Registry (BarrettNET) and a Case-Control Population in Germany
Melissa Schmidt, Donna P. Ankerst, Yiyao Chen, Maria Wiethaler, Julia Slotta-Huspenina, Karl-Friedrich Becker, Julia Horstmann, Florian Kohlmayer, Andreas Lehmann, Birgit Linkohr, Konstantin Strauch, Roland M. Schmid, Anne S. Quante, and Michael Quante

385  Insulin-like Growth Factor-1, Insulin-like Growth Factor Binding Protein-3 and the Incidence of Malignant Neoplasms in a Nested Case-Control Study
Yasushi Adachi, Masanori Nojima, Mitsuru Mori, Ryogo Himori, Toshiyuki Kubo, Hiro-o. Yamano, Yingsong Lin, Kenji Wakai, and Akiko Tamakoshi; for JACC study

395  Low Colorectal Cancer Screening Uptake and Persistent Disparities in an Underserved Urban Population

403  Risk Factors for Recurrence in Patients with Atypical Endometrial Hyperplasia and Endometroid Adenocarcinoma after Fertility-Sparing Treatments
Jie Yin, Shuai Ma, Ying Shan, Yongxue Wang, Yan Li, Ying Jin, and Lingya Pan

411  Knowledge of Potential Harms and Benefits of Tamoxifen among Women Considering Breast Cancer Preventive Therapy
Rachael Jane Thorneloe, Louise Hazel Hall, Fiona Mary Walter, Lucy Side, Kelly Elizabeth Lloyd, and Samuel George Smith; on Behalf of the ENGAGE Investigators
The cover image shows the structure of pembrolizumab, a well-known immune checkpoint inhibitor used widely in treatment of certain advanced cancers, where it sometimes provides dramatic clinical benefit. In this issue, a case report (beginning on page 351) by Mancuso and colleagues provides justification for further study of checkpoint inhibitors in the context of cancer prevention, as distinct from treatment. A patient with Muir–Torre syndrome, a DNA repair deficiency, was observed to regularly develop many neoplastic and hyperplastic lesions during follow up over many years. After he received pembrolizumab for treatment of his bladder cancer, not only did he achieve a complete response, but new lesions stopped appearing. While a case report cannot be used to prove or disprove a hypothesis, it is possible that at least for patients with DNA repair deficits, and perhaps more generally, immune checkpoint blockade may allow “immune-interception” of clinically undetectable neoplastic lesions, accounting for the unexpected lack of new neoplasms in this patient. Clinical trials of “immunoprevention” will be challenging, but there is a clear rationale for work in this area, both in the lab and the clinic.